LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Reata failed to produce MOXIe Part 2 study results sufficient to support marketing approval for omaveloxolone for the treatment of FA from the FDA without additional evidence. It was foreseeable that the FDA would not approve omaveloxolone for the treatment of FA based on the MOXIe Part 2 study alone. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Reata, investors suffered damages.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.